J&J'S CONOR TO PRESENT STENT CLINICAL TRIAL RESULTS IN MAY

Conor Medsystems, a subsidiary of Johnson & Johnson, announced it plans to present the results for its COSTAR II pivotal clinical trial at the EuroPCR meeting in Barcelona, Spain, in May.

"The last patient was followed up in February 2007, and we expect the independent clinical research organization to commence the data analysis in March, providing sufficient time for presentation at the upcoming EuroPCR meeting," said Michael Boennighausen, general manager at Conor.

The COSTAR II clinical trial is a randomized, single-blind, non-inferiority study comparing Conor's CoStar cobalt chromium paclitaxel-eluting stent with Boston Scientific's Taxus Express2 drug-eluting stent in the treatment of de novo lesions in patients with single- or multi-vessel coronary artery disease. It includes 1,700 patients from more than 70 clinical sites.

EuroPCR is the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions.